New research into benefits of Prilactone for CHF
A new publication into the benefits of spironolactone (Prilactone - CEVA Animal Health) has supported its use as part of first-line therapy for the treatment of dogs with congestive heart failure caused by mitral heart disease, according to CEVA. The double-blind placebo-controlled study 1 involved 212 dogs on either spironolactone or a placebo, in addition to conventional therapy including an ACE inhibitor and furosemide. It revealed that over a 15 month period 25.5% of dogs either died, were euthanased or severely worsened in the placebo group compared to 10.8% in the spironolactone group. This...